Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott will release its second-quarter 2020 financial results on July 16, 2020, before the market opens. A live webcast of the earnings conference call is scheduled for 8:30 a.m. CT and can be accessed via Abbott's Investor Relations website. This follows the company's commitment to keep stakeholders informed about its financial performance. Abbott operates globally in healthcare, offering solutions across diagnostics, medical devices, nutritionals, and generic medicines, supported by a workforce of 107,000 in over 160 countries.
Abbott announced that its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system has been cleared by the U.S. FDA for adults and children aged 4 and older with diabetes. This system features optional real-time alarms and measures glucose levels every minute, offering a 14-day wear time, the longest for a self-applied iCGM sensor. Its combined mean absolute relative difference (MARD) is 9.3%, ensuring high accuracy. Priced at a third of other CGMs, Abbott aims to make this technology accessible while enhancing diabetes care.
Abbott (NYSE: ABT) announced promising data showing that its FreeStyle Libre system significantly lowers hemoglobin A1c (HbA1c) levels in type 2 diabetes patients, regardless of insulin use. Results from a study presented at the American Diabetes Association (ADA) indicated a drop of 0.8% after six months and 0.6% after one year. Notably, non-insulin users experienced the most significant reductions. Additionally, using the system was linked to a 30% reduction in acute diabetes events and a 13% decrease in hospitalizations, potentially lowering healthcare costs.